Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Products under Development by Stage of Development | 7 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Products under Development by Therapy Area | 8 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Products under Development by Indication | 9 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Products under Development by Companies | 12 | 2 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Companies Involved in Therapeutics Development | 18 | 7 |
| Alvogen Korea Co., Ltd. | 18 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 19 | 1 |
| CJ HealthCare Corp. | 20 | 1 |
| Esperion Therapeutics, Inc. | 21 | 1 |
| Kotobuki Pharmaceutical Co., Ltd. | 22 | 1 |
| Merck &Co., Inc. | 23 | 1 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 24 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Drug Profiles | 25 | 8 |
| (atorvastatin calcium + ezetimibe) Drug Profile | 25 | 1 |
| (atorvastatin calcium + ezetimibe) Drug Profile | 26 | 1 |
| (bempedoic acid + ezetimibe) Drug Profile | 27 | 1 |
| (ezetimibe + rosuvastatin calcium) Drug Profile | 28 | 1 |
| (ezetimibe + rosuvastatin calcium) Drug Profile | 29 | 1 |
| (ezetimibe + rosuvastatin calcium) Drug Profile | 30 | 1 |
| HS-25 Drug Profile | 31 | 1 |
| KT-6971 Drug Profile | 32 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Dormant Projects | 33 | 1 |
| Niemann Pick C1 Like Protein 1 (NPC1L1) Featured News &Press Releases | 34 | 3 |
| Feb 15, 2016: Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe) | 34 | 1 |
| Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects | 35 | 1 |
| May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia | 35 | 1 |
| Jan 02, 2013: Merck Announces FDA Acknowledgement Of Resubmission Of New Drug Application For Ezetimibe/Atorvastatin Tablets | 35 | 1 |
| Apr 04, 2012: Frontage Successfully Files IND To Launch US Statin Study | 36 | 1 |
| Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor | 36 | 1 |
| Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns | 36 | 1 |
| Appendix | 37 | 2 |
| Methodology | 37 | 1 |
| Coverage | 37 | 1 |
| Secondary Research | 37 | 1 |
| Primary Research | 37 | 1 |
| Expert Panel Validation | 37 | 1 |
| Contact Us | 37 | 1 |
| Disclaimer | 38 | 1 |